Clinical trials: Blood Plasma Therapy
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Background: Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatment (relapse) in almost all people; MM may also not respond to initial treatment (refractory).
- Trial name
- NCT06876142
- Testing
- Mirdametinib, Sirolimus
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Knee Osteoarthritis
Knee Osteoarthritis and Rehabilitation
Osteoarthritis (OA) is a chronic degenerative disease of articular cartilage that causes hypertrophic changes in bone. OA is a non-inflammatory progressive musculoskeletal disease and is one of the most common degenerative…
- Trial name
- NCT06432842
- Testing
- Laser Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Karabuk University
Muscle Injury
Platelet-Rich Plasma in Acute Muscle Injuries
OBJECTIVE: To evaluate the effect of Platelet Rich Plasma (PRP) injection in muscle injuries. The investigators check football players in the acute phase of hamstrings or quadriceps injuries. Efficacy and safety are evaluated.
- Trial name
- NCT03676205
- Testing
- PRP, Traumeel
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- University of the Basque Country (UPV/EHU)
Myeloma Multiple, Myeloma
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple…
- Conditions
- Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
- Trial name
- ClaSPd (NCT04843579)
- Testing
- Selinexor, Clarithromycin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I
- Trial name
- RithMM (NCT03428373)
- Testing
- Rivaroxaban, ASA
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma
CAR T-cell Therapy in Patients With Renal Dysfunction
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
- Conditions
- Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT05909059
- Testing
- Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Waldenstrom Macroglobulinemia
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
In Waldenström macroglobulinemia (WM) conventional chemotherapy induces only low complete remission (CR) rates and responses of short duration compared to other indolent lymphomas.
- Trial name
- NCT03620903
- Testing
- Ibrutinib / Bortezomib / Rituximab
- Where
- 12 sites in Germany, Greece
- Volunteers
- 53 people
- Sponsor
- Christian Buske
Graft-versus-host Disease
Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD
The purpose of this study is to evaluate the safety and efficacy of autologous Platelet Rich Plasma (PRP) and Platelet Poor Plasma (PPP) eye drops four times a day in the treatment of ocular graft versus host disease (O-GVHD).
- Trial name
- NCT02561520
- Testing
- PRP eye drops, PPP eye drops
- Where
- United States
- Sponsor
- Ladan Espandar
HIV Infections, AIDS
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia.
- Conditions
- HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
- Trial name
- NCT00346697
- Testing
- Omega-3 fatty acid administration
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brown, Todd, M.D., Ph.D.
Multiple Myeloma in Older Patients
Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient.
- Trial name
- MYELOME-PA (NCT02063113)
- Testing
- Vulnerability and therapeutic changes in older patients with multiple myeloma.
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
Daratumumab is a new treatment for patients with myeloma. While many patients benefit from this treatment some do not and the mechanism(s) of failure are poorly understood.
- Trial name
- DARA (NCT02419118)
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Vejle Hospital
Bleeding, Ischemic Stroke
The Relationship Between Clotting Factor VIII and Bleeding Adverse Reactions in Patients Under the Therapies of Thrombolysis, Anticoagulation and Anti-platelet
The purpose of this study is to determine whether Plasma Factor VIII Levels are related to the treatment of bleeding in ischemic stroke（IS）.
- Trial name
- NCT02677818
- Where
- China
- Sponsor
- Zhujiang Hospital
Relapsed or Refractory Multiple Myeloma
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
The main purpose of this Phase I study is to access the safety and tolerability of Y150 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.
- Trial name
- NCT05011097
- Testing
- Y150
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Hemorrhage
An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
This observational cohort study is designed to obtain product safety information from the routine clinical setting within large, diverse, community-based populations.
- Trial name
- NCT02319460
- Testing
- Kcentra®, Plasma
- Where
- United States
- Volunteers
- 2,238 people
- Sponsor
- CSL Behring
Multiple Myeloma
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
The purpose of this research is to estimate the effectiveness of a response adapted approach with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed standard risk multiple myeloma.
- Trial name
- NCT01054144
- Testing
- Lenalidomide, Prednisone, Dexamethasone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma and Plasma Cell Neoplasm
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477971
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Insulin Resistance, Deteriorated Glucose Homeostasis
Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance
The incretin effect in patients with type two diabetes is reduced. The investigators have previously shown that it is possible to induce a defect in the incretin effect in healthy individuals.
- Conditions
- Insulin Resistance, Deteriorated Glucose Homeostasis, Inactivity
- Trial name
- NCT01173978
- Testing
- Steroid hormone, No intervention
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Multiple Myeloma
TCD Followed by autoSCT for Newly Diagnosed MM Patients
Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by high dose chemotherapy with autologous stem…
- Trial name
- NCT00349115
- Testing
- Thalidomide
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Korean Multiple Myeloma Working Party
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
RATIONALE: The influenza vaccine may help prevent flu in patients who have undergone stem cell transplant. PURPOSE: This clinical trial is studying how well the influenza vaccine works in preventing flu in patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00952185
- Testing
- cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cardiovascular Complication
Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients
The aim of the study is to test whether pre-operative oral supplementation with L-arginine results in a significant reduction of peri-operative cardiovascular complication rate in unselected patients undergoing major abdominal or…
- Trial name
- NCT01413815
- Testing
- L-arginine
- Where
- 5 sites in Germany
- Volunteers
- 269 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.